From editor-in-chief

I am pleased to present the second issue of the journal Quality Clinical Practice for the year 2026. This volume brings together materials that reflect a broad spectrum of current challenges in clinical pharmacology, pharmacotherapy, and related disciplines – ranging from fundamental mechanisms of drug interactions to practical applications of digital technologies in healthcare.

The issue opens with a pharmacoepidemiological study on the 15‑year dynamics of glucagon‑like peptide‑1 receptor agonist consumption in the Russian Federation. The work demonstrates an impressive 733‑fold increase in the use of this drug class, mirroring global trends in the management of type 2 diabetes mellitus and obesity.

The drug safety section features a comprehensive review of drug‑induced lesions of the digestive system, in which the authors thoroughly analyse the mechanisms of adverse reactions from the oral cavity to the liver and pancreas. Particular attention is paid to NSAID‑induced gastropathies and antibiotic‑associated intestinal damage.

Two materials are devoted to modern pharmacovigilance:

• One examines international risk management strategies for medicinal products (REMS in the USA and EU‑RMP in the European Union).

• The other review analyses the role of digital technologies and artificial intelligence in pharmacovigilance systems, including the prospects for their implementation in the practice of the Eurasian Economic Union member states.

The block of real‑world clinical practice research includes three studies:

1. The first reports on the experience of using olokizumab in comorbid patients with COVID‑19 – it is shown that pre‑emptive therapy significantly reduces mortality and the need for respiratory support.

2. The second study presents an algorithm for optimising empirical therapy of urinary tract infections based on local microbiological monitoring.

3. The third investigation analyses the specific features of antiviral therapy in patients with COVID‑19 complicated by acute myocardial infarction, revealing potential cardioprotective properties of favipiravir.

A review of the key trends in clinical research development for 2026 highlights seven major directions:

• Artificial intelligence;

• Hybrid trial designs;

• Real‑world clinical data;

• Research site readiness;

• Patient partnership;

• Advanced therapy medicinal products;

• Electronic informed consent.

The clinical audit section presents a retrospective analysis of NSAID prescriptions and the “Triple Whammy” phenomenon in polymorbid outpatients. The authors demonstrate a high frequency of potentially nephrotoxic combinations in patients with reduced renal function, underscoring the need for computerised physician decision support systems.

In the clinical pharmacokinetics section, a systematic review of the pharmacokinetics and pharmacodynamics of linezolid in children of different age groups is presented. The necessity of therapeutic drug monitoring for individualised dosing, especially in neonates and preterm infants, is substantiated.

A pharmacogenetic investigation revealed associations of CYP1A2 and CYP1B1 gene polymorphisms with endometrial thickness on the day of ovulation trigger administration in patients with anovulatory infertility undergoing IVF programmes, opening perspectives for personalised endometrial preparation protocols.

The internal medicine section publishes a study on lipopolysaccharide‑binding systems and endothelial nitric oxide synthase in patients with gout. For the first time, a significant positive correlation between BPI and NOS3 levels has been identified, indicating a link between innate immunity and endothelial function.

The issue concludes with a review of modern ultrasound diagnostic capabilities for pelvic floor dysfunction, covering in detail transperineal, 3D and 4D approaches, as well as the role of the method in selecting conservative versus surgical management strategies.

I thank the authors for their high‑quality and timely contributions, as well as the members of the editorial board and reviewers for their invaluable input in preparing this issue. I am confident that the presented materials will be useful for practising physicians, clinical pharmacologists, researchers, and healthcare administrators.

I invite you to active cooperation and look forward to receiving your new publications!

Yours sincerely,
Sergey Kensarinovich Zyryanov
Editor‑in‑Chief of the journal Good Clinical Practice